Oxaliplatin: a review in the era of molecularly targeted therapy
T Alcindor, N Beauger - Current oncology, 2011 - mdpi.com
Objective: To review preclinical and clinical data for oxaliplatin in the current context of
molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and …
molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and …
Oxaliplatin: a review of approved uses
A Stein, D Arnold - Expert opinion on pharmacotherapy, 2012 - Taylor & Francis
Introduction: Oxaliplatin, a second-generation platinum analog, has evolved as one of the
most important therapeutic agents in colorectal cancer (CRC) treatment. It has had a major …
most important therapeutic agents in colorectal cancer (CRC) treatment. It has had a major …
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working …
PM LoRusso, K Venkatakrishnan, RK Ramanathan… - Clinical Cancer …, 2012 - AACR
Purpose: The proteasome inhibitor bortezomib undergoes oxidative hepatic metabolism.
This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib …
This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib …
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
C Eng - Nature Reviews Clinical Oncology, 2009 - nature.com
Among the many chemotherapeutic options for metastatic colorectal cancer, none has
shown clear superiority in efficacy. All pharmacologic agents in current use have been …
shown clear superiority in efficacy. All pharmacologic agents in current use have been …
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
O Mir, R Coriat, P Boudou-Rouquette, S Ropert… - Medical oncology, 2012 - Springer
Some patients with advanced hepatocellular carcinoma (HCC) progressing under sorafenib
remain eligible for further systemic therapy. Little is known on the feasibility of systemic …
remain eligible for further systemic therapy. Little is known on the feasibility of systemic …
[HTML][HTML] Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma
HK Sanoff, S Bernard, RM Goldberg… - Gastrointestinal …, 2011 - ncbi.nlm.nih.gov
Background: Hepatocellular carcinoma (HCC) is frequently resistant to chemotherapy.
However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in …
However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in …
[HTML][HTML] Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy
Background The survival of colorectal cancer patients is frequently determined by the extent
of metastatic invasion to the liver; in cases of major involvement, therapeutic strategies are …
of metastatic invasion to the liver; in cases of major involvement, therapeutic strategies are …
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
A Patrikidou, I Sinapi, H Regnault, F Fayard… - Investigational new …, 2014 - Springer
Background Sorafenib is the only systemic treatment that has shown a significant benefit in
overall survival (OS) and in progression-free survival (PFS) in advanced hepatocellular …
overall survival (OS) and in progression-free survival (PFS) in advanced hepatocellular …
[HTML][HTML] Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
U Schmid, C Doege, C Dallinger, M Freiwald - Pulmonary Pharmacology & …, 2018 - Elsevier
Background Nintedanib is a potent intracellular inhibitor of tyrosine kinases, including the
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …
receptor kinases vascular endothelial growth factor, platelet-derived growth factor and …
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …
Y Liu, H Yue, S Xu, F Wang, N Ma, K Li, L Qiao… - International journal of …, 2015 - Springer
Background Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …